Skip to Content
Merck
All Photos(1)

Key Documents

More Documents

Q0100000

Quinidine sulfate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Quinidine sulfate salt dihydrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C40H48N4O4 · H2O4S · 2H2O
CAS Number:
6591-63-5
Molecular Weight:
782.94
MDL number:
MFCD00149346
UNSPSC Code:
41116107
PubChem Substance ID:
329823855
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

quinidine

manufacturer/tradename

EDQM

mp

212-214 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

[H]O[H].[H]O[H].OS(O)(=O)=O.[H][C@]1(CN2CCC1C[C@]2([H])[C@@H](O)c3ccnc4ccc(OC)cc34)C=C.[H][C@]5(CN6CCC5C[C@]6([H])[C@@H](O)c7ccnc8ccc(OC)cc78)C=C

InChI

1S/2C20H24N2O2.H2O4S.2H2O/c2*1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;1-5(2,3)4;;/h2*3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;(H2,1,2,3,4);2*1H2/t2*13-,14?,19-,20+;;;/m11.../s1

InChI key

ZHNFLHYOFXQIOW-WFTMRWCJSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Quinidine sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Class IA antiarrhythmic; potassium channel blocker.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P301 + P312 + P330

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Motoya Suzuki et al.
Xenobiotica; the fate of foreign compounds in biological systems, 44(11), 1039-1045 (2014-05-21)
1.  This study was aimed to characterize gastrointestinal absorption of digoxin using wild-type (WT) and multidrug resistance protein 1a [mdr1a; P-glycoprotein (P-gp)] knockout (-/-) rats. 2.  In WT rats, the area under the plasma concentration-time curve (AUC) of oral digoxin
Yuki Ogawa et al.
European journal of pediatrics, 174(4), 509-518 (2014-09-25)
This study aimed to determine the population pharmacokinetics of doxapram in low-birth-weight (LBW) infants. A total of 92 serum concentration measurements that were obtained from 34 Japanese neonates were analyzed using nonlinear mixed-effect modeling (NONMEM). Estimates generated by NONMEM indicated
Maria Addolorata Saracino et al.
Journal of pharmaceutical and biomedical analysis, 95, 61-67 (2014-03-19)
A rapid and reliable analytical method has been developed to quantify the melatonergic antidepressant agomelatine in three matrices, and namely saliva, plasma and dried blood spots. The method is based on the use of liquid chromatography with fluorimetric detection exploiting
Mikiko Tsukimoto et al.
Biopharmaceutics & drug disposition, 36(1), 15-33 (2014-09-30)
Aliskiren is a substrate for P-glycoprotein (P-gp) and is metabolized via cytochrome P450 3A4 (CYP3A4). The aim of the present study was to assess whether P-gp influenced the pharmacokinetics of aliskiren and also if drug-drug interactions (DDIs) mediated through P-gp
Laura Kervezee et al.
The AAPS journal, 16(5), 1029-1037 (2014-06-12)
Nearly all bodily processes exhibit circadian rhythmicity. As a consequence, the pharmacokinetic and pharmacodynamic properties of a drug may also vary with time of day. The objective of this study was to investigate diurnal variation in processes that regulate drug
View All Related Papers

Protocols

LC/MS/MS Analysis of Drugs in Plasma on Ascentis® Express C18 after Extraction using SPME LC Tips

LC/MS/MS Analysis of Drugs in Plasma on Ascentis® Express C18 after Extraction using SPME LC Tips

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service